DOI QR코드

DOI QR Code

The usefulness of newly developed R2CHA2DS2-VASc score and comparison with CHADS2 and CHA2DS2-VASc scores in atrial fibrillation patients

심방세동 환자에서 새로 개발된 R2CHA2DS2-VASc score 유용성 및 CHADS2, CHA2DS2-VASc scores와의 비교연구

  • Kwak, Jae-Hoon (Department of Internal Medicine, Gyeongju Hospital, Dongguk University College of Medicine) ;
  • Yeo, Se-Hwan (Department of Internal Medicine, Gyeongju Hospital, Dongguk University College of Medicine) ;
  • Kim, Yeo-Un (Department of Internal Medicine, Gyeongju Hospital, Dongguk University College of Medicine) ;
  • Lee, Jin-Suk (Department of Internal Medicine, Gyeongju Hospital, Dongguk University College of Medicine) ;
  • Kim, Byong-Kyu (Division of Cardiology, Department of Internal Medicine, Gyeongju Hospital, Dongguk University College of Medicine) ;
  • Chung, Jin-Wook (Division of Cardiology, Department of Internal Medicine, Gyeongju Hospital, Dongguk University College of Medicine) ;
  • Bae, Jun-Ho (Division of Cardiology, Department of Internal Medicine, Gyeongju Hospital, Dongguk University College of Medicine) ;
  • Nah, Deuk-Young (Division of Cardiology, Department of Internal Medicine, Gyeongju Hospital, Dongguk University College of Medicine) ;
  • Lee, Kwan (Department of Preventive Medicine, Dongguk University College of Medicine)
  • 곽재훈 (동국대학교 의과대학 경주병원 내과) ;
  • 여세환 (동국대학교 의과대학 경주병원 내과) ;
  • 김여운 (동국대학교 의과대학 경주병원 내과) ;
  • 이진석 (동국대학교 의과대학 경주병원 내과) ;
  • 김병규 (동국대학교 의과대학 경주병원 심장내과) ;
  • 정진욱 (동국대학교 의과대학 경주병원 심장내과) ;
  • 배준호 (동국대학교 의과대학 경주병원 심장내과) ;
  • 나득영 (동국대학교 의과대학 경주병원 심장내과) ;
  • 이관 (동국대학교 의과대학 예방의학교실)
  • Received : 2016.04.07
  • Accepted : 2016.05.27
  • Published : 2016.06.30

Abstract

Background: The decision to administer oral anticoagulation therapy depends on accurate assessment of stroke risk in patients with atrial fibrillation (AF). Various stroke risk stratification schemes have been developed to help inform clinical decision making. The CHADS2 and CHA2DS2-VASc scores have been used in estimating the risk of stroke in patients with AF. Recently R2CHA2DS2-VASc score was developed. The objective of the current study is to validate the usefulness of the R2CHA2DS2-VASc score and to compare the accuracy of the CHADS2, CHA2DS2-VASc, and R2CHA2DS2-VASc scores in predicting a patient's risk of stroke. Methods: Based on medical records, we conducted a retrospective study of patients hospitalized with AF from March 2011 to July 2013. A total of 448 AF patients were included in this study. The receiver operating characteristic (ROC) curve analysis in MedCalc was used for comparison with respective diagnostic values. Results: The patient characteristics showed male predominance (60.9%). Among the 448 AF patients, 131 (29.2%) patients had strokes during the study. A R2CHA2DS2-VASc score of more than 5 is the optimal cut-off value for prediction of stroke. A risk score of three, the area under the ROC curve (AUC) of R2CHA2DS2-VASc score (AUC 0.631; 95% confidence interval, 0.585-0.679) was the highest. A significant difference was observed between AUC for R2CHA2DS2-VASc, CHADS2, and CHA2DS2-VASc scores, but no meaningful difference between CHADS2 and CHA2DS2-VASc scores. Conclusion: We determined the usefulness of the R2CHA2DS2-VASc score, which showed better association with stroke than the CHADS2 and CHA2DS2-VASc scores.

Keywords

References

  1. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J 1996;131:790-5. https://doi.org/10.1016/S0002-8703(96)90288-4
  2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-4. https://doi.org/10.1001/archinte.1987.00370090041008
  3. Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke 2005;36:360-6. https://doi.org/10.1161/01.STR.0000153002.56324.8c
  4. Lip GY. The $CHA_2DS_2-VASc$ score for stroke risk stratification in patients with atrial fibrillation: a brief history. Eur Heart J 2015;36:2880-5.
  5. Kiliszek M, Szpakowicz A, Filipiak KJ, Koltowski L, Poludniewska D, Szymanski F, et al. CHA2DS2-VASc and R2CHA2DS2-VASc scores have predictive value in patients with acute coronary syndromes. Pol Arch Med Wewn 2015;125:545-52.
  6. O'Brien EC, Simon DN, Thomas L, Fonarow GC, Kowey PR, Mahaffey KW, et al. Comparative performance of the R2Chads2, Chads2, and Cha2Ds2-vasc scores in atrial fibrillation. Circulation 2015;132(Suppl 3):A17202.
  7. Kornej J, Lip GY. Comparing the 'new' R2CHADS2 with the 'old' CHA2DS2-VASc scores for predicting thromboembolism in patients undergoing atrial fibrillation ablation: new does not mean better. Can J Cardiol 2014;30:385-7. https://doi.org/10.1016/j.cjca.2013.12.015
  8. Bautista J, Bella A, Chaudhari A, Pekler G, Sapra KJ, Carbajal R, et al. Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure. Clin Kidney J 2015;8:226-31. https://doi.org/10.1093/ckj/sfv006
  9. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92. https://doi.org/10.1161/01.CIR.0000145172.55640.93
  10. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-9. https://doi.org/10.1016/j.ahj.2005.04.017
  11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. https://doi.org/10.1056/NEJMoa0905561
  12. Jang IM, Lee KB, Ahn MY. A rate of anticoagulation for the prevention of ischemic stroke in the patients with atrial fibrillation. J Soonchunhyang Med Coll 2008;14:285-9.